[Below are the Areas of Interest for consideration for GSK’s Assets:]

[RSV]
• Studies to assess Arexvy real-world effectiveness/impact in adult population at increased risk of RSV disease due to age, underlying condition or immunosuppression

[Shingrix]
•   Evidence and consequences of sub-clinical reactivation of Varicella Zoster Virus (VZV) (including but not limited to cardiovascular outcomes, dementia, cognitive decline and aging)
•   Durability of protection against herpes zoster (and its complications) in real-world settings in immunocompromised individuals over the longer term (follow-up of ≥5 years post-vaccination with RZV)

[Neisseria]
•   Epidemiology, burden of disease and IMD risk across age groups and geographic regions
•   Mechanisms and synergistic activities of antibodies induced by 4CMenB
•   Evaluating the cross-protective features and novel dosing schemes of 4CMenB

[Established]
•   NA

[Pneumococcal]
•   Studies to investigate the evolving serotype-specific pneumococcal disease burden (incl. epidemiological and/or economic endpoints) in adult and paediatric population

[Early]
•   NA